BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical market. Underlying issues regarding the operating environment will prevent an immediate uptick in multinational drugmaker interest; rather, this will be a gradual process. Nevertheless, there has been a notable boost in international cooperation with European counterparts in particular over the past six months. This will support the Iranian government's aim to attract greater direct investment from foreign pharmaceutical companies.
عضو شوید
عضویت سریع
آمار مطالب
آمار بازدید
